Your browser doesn't support javascript.
loading
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij, Monique K; Joosse, Arjen; Suijkerbuijk, Karijn P M; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; Blank, Christian U; Boers-Sonderen, Marye J; van den Eertwegh, Alfonsus J M; de Groot, Jan Willem B; Haanen, John B A G; Hospers, Geke A P; Piersma, Djura; van Rijn, Rozemarijn S; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Westgeest, Hans M; Wouters, Michel W J M; Dekkers, Olaf M; Kapiteijn, Ellen.
Afiliación
  • van der Kooij MK; Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.
  • Joosse A; Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.
  • Suijkerbuijk KPM; Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
  • Aarts MJB; Department of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands.
  • van den Berkmortel FWPJ; Department of Medical Oncology, Zuyderland Medical Center, 6130 MB, Sittard-Geleen, The Netherlands.
  • Blank CU; Department of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Boers-Sonderen MJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, The Netherlands.
  • van den Eertwegh AJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ, Amsterdam, The Netherlands.
  • de Groot JWB; Isala Oncology Center, Isala, 8000 GK, Zwolle, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
  • Piersma D; Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.
  • van Rijn RS; Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands.
  • van der Veldt AAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.
  • Vreugdenhil G; Department of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB, Veldhoven, The Netherlands.
  • Westgeest HM; Department of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV, Breda, The Netherlands.
  • Wouters MWJM; Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands.
  • Dekkers OM; Department of Surgical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Kapiteijn E; Department of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.
Br J Cancer ; 128(5): 707-710, 2023 03.
Article en En | MEDLINE | ID: mdl-36564561

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Melanoma Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptor de Muerte Celular Programada 1 / Melanoma Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos